These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6715296)

  • 21. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D1 receptors mediated vacuous chewing in the rat: a model of tardive dyskinesia.
    Diana M; Collu M
    Pharmacol Res; 1990; 22 Suppl 3():45. PubMed ID: 2097639
    [No Abstract]   [Full Text] [Related]  

  • 23. The pathophysiologic basis of tardive dyskinesia.
    Baldessarini RJ
    Psychopharmacol Bull; 1978 Oct; 14(4):79-81. PubMed ID: 30114
    [No Abstract]   [Full Text] [Related]  

  • 24. [Neuroleptic-induced dopaminergic supersensitivity following intermittent and continuous haloperidol administrations in rats].
    Sato M; Kashihara K; Harada T
    Seishin Shinkeigaku Zasshi; 1984; 86(10):841-4. PubMed ID: 6522512
    [No Abstract]   [Full Text] [Related]  

  • 25. Altered receptor sensitivity following chronic drug administration in man: the tardive dyskinesia model [proceedings].
    Rubovits R
    Psychopharmacol Bull; 1977 Jan; 13(1):49-50. PubMed ID: 402011
    [No Abstract]   [Full Text] [Related]  

  • 26. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tardive dyskinesia].
    Roos RA
    Ned Tijdschr Geneeskd; 1982 Nov; 126(47):2153-7. PubMed ID: 7177228
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic studies of tardive dyskinesia.
    Chase TN; Tamminga CA
    Adv Biochem Psychopharmacol; 1980; 24():457-61. PubMed ID: 7405673
    [No Abstract]   [Full Text] [Related]  

  • 29. Dopamine synthesis: tolerance to haloperidol and supersensitivity to apomorphine depend on presynaptic receptors.
    Biggio G; Casu M; Klimek V; Gessa GL
    Adv Biochem Psychopharmacol; 1980; 24():17-22. PubMed ID: 6996441
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopaminergic and GABAergic aspects of tardive dyskinesia [proceedings].
    Casey DE; Gerlach J; Magelund G; Christensen TR
    Psychopharmacol Bull; 1981 Jan; 17(1):49-50. PubMed ID: 7232658
    [No Abstract]   [Full Text] [Related]  

  • 31. [Tardive dyskinesia].
    Kato M; Watanabe K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):183-7. PubMed ID: 12876961
    [No Abstract]   [Full Text] [Related]  

  • 32. Presynaptic dopamine receptors in striatal nerve endings: absence of haloperidol-induced supersensitivity.
    Raiteri M; Cerrito F; Casazza G; Levi G
    Adv Biochem Psychopharmacol; 1980; 24():37-43. PubMed ID: 7405669
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
    Noda Y; Kurumiya S; Miura Y; Oka M
    J Pharmacol Exp Ther; 1993 May; 265(2):745-51. PubMed ID: 8098763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-blind study of ECT in patients with tardive dyskinesia.
    Asnis GM; Leopold MA
    Am J Psychiatry; 1978 Oct; 135(10):1235-7. PubMed ID: 696908
    [No Abstract]   [Full Text] [Related]  

  • 36. ECT and tardive dyskinesia.
    Hay DP; Hay L; Blackwell B; Spiro HR
    J Geriatr Psychiatry Neurol; 1990; 3(2):106-9. PubMed ID: 1976309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging CNS receptors: the dopaminergic system.
    Wagner HN
    Hosp Pract (Off Ed); 1984 Jun; 19(6):187-91, 195-8, 202. PubMed ID: 6144688
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful electroconvulsive treatment of depression associated with a marked reduction in the symptoms of tardive dyskinesia.
    Nobuhara K; Matsuda S; Okugawa G; Tamagaki C; Kinoshita T
    J ECT; 2004 Dec; 20(4):262-3. PubMed ID: 15591862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.